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Abstract
Endoplasmic reticulum (ER) stress-mediated cell death is an emerging target for human chronic disorders, including
neurodegeneration and diabetes. However, there is currently no treatment for preventing ER stress-mediated cell death. Here,
we show that mesencephalic astrocyte-derived neurotrophic factor (MANF), a neurotrophic factor secreted from ER stressed
cells, prevents ER stress-mediated β cell death and enhances β cell proliferation in cell and mouse models of Wolfram
syndrome, a prototype of ER disorders. Our results indicate that molecular pathways regulated by MANF are promising
therapeutic targets for regenerative therapy of ER stress-related disorders, including diabetes, retinal degeneration,
neurodegeneration, and Wolfram syndrome.

Introduction
Growing evidence indicates that endoplasmic reticulum (ER)
stress plays a critical role in β cell death in type 1 and type 2
diabetes, as well as in neurodegenerative disorders, including
Parkinson’s disease and amyotrophic lateral sclerosis [1–5].
Despite the underlying importance of ER stress in β cell
death, there is currently no diabetes treatment targeting the ER
due to the complex nature of type 1 and type 2 diabetes. Our
strategy for overcoming this challenge is to focus on a
monogenic form of diabetes, Wolfram syndrome. Wolfram
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syndrome is a rare disease characterized by juvenile-onset
diabetes mellitus, optic nerve atrophy, and neurodegeneration
[6, 7]. As this syndrome is caused by mutations in the WFS1
gene which is involved in ER calcium homeostasis and ER
stress-mediated cell death, it is ideal for testing potential new
treatments targeting the ER [8–14].
Mesencephalic astrocyte-derived neurotrophic factor
(MANF) is a trophic factor whose expression and secretion
is enhanced by ER stress and ER calcium depletion [15–
18]. It has been demonstrated that MANF plays a critical
role in the survival of ER stressed β cells and neurons
[19, 20], raising the possibility that MANF-based treatment
can be beneﬁcial for patients suffering from ER stressrelated disorders, including Wolfram syndrome. Here we
show that MANF-based treatment prevents β cell death and
enhances β cell proliferation in cell and mouse models of
Wolfram syndrome. Our results indicate that molecular
pathways regulated by MANF are promising drug targets
for ER stress-related disorders, including β cell death in
diabetes and Wolfram syndrome.

Materials and methods
Cell culture
Manf knockout INS-1 832/13 cells and Wfs1 knockout INS-1
832/13 cells were created in collaboration with the Genome
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Engineering and Induced Pluripotent Stem Cell (iPSC)
Center at Washington University using CRISPR-Cas9 genome editing techniques. INS-1 832/13 cells in which Wfs1
expression can be suppressed by doxycycline-inducible
shRNA directed against Wfs1 (INS-1 DOX-shWfs1) were
generated as described previously [9]. Brieﬂy, INS-1 832/13
cells stably expressing pTetR were transduced with lentivirus
expressing pTER(H1/tetO)-shWfs1. INS-1 DOX-shWfs1
were cultured in 2 µg/ml doxycycline (MilliporeSigma, St.
Louis, MO) for 48 h before isolation of protein and RNA,
and glucose-stimulated insulin secretion (GSIS) assay. INS-1
832/13 cells stably overexpressing MANF (MANF-OE)
were created by transducing INS-1 832/13 cells with lentivirus expressing human MANF. INS-1 832/13 cells were
cultured in RPMI 1640 (Thermo Fisher Scientiﬁc, Waltham,
MA) supplemented with 10% FBS (Thermo Fisher
Scientiﬁc), 1 mM sodium pyruvate (Thermo Fisher Scientiﬁc), 100 nM β-mercaptoethanol (MilliporeSigma), and
penicillin–streptomycin
(Thermo
Fisher
Scientiﬁc).
Tetracycline-free FBS (Takara Bio USA, Mountain View,
CA) was used for culturing INS-1 DOX-shWfs1.

Animal experiments
Wfs1 β cell-speciﬁc knockout (βWfs1(−/−)) mice were generated by breeding the Cre recombinase driven by rat
insulin promoter (Rip2-Cre) transgenic mice (originally
from Dr Pedro Herrera) with Wfs1 ﬂoxed mice [21]. All
animal experiments were performed according to procedures approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine (A-3381-01).

Immunoblot analysis
INS-1 832/13 cells were washed in cold PBS and lysed with
M-PER reagent (Thermo Fisher Scientiﬁc) containing
Complete™ protease inhibitor cocktail (MilliporeSigma).
The equivalent amounts of cell lysates were resolved by
SDS-PAGE using 4–20% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad Laboratories, Hercules, CA) and
blotted onto Immobilon-P PVDF membrane (0.45 µm)
(MilliporeSigma). The following primary antibodies were
used for detecting the protein of interest; WFS1 antibody
(Proteintech, Rosemont, IL), cleaved caspase-3, GAPDH,
alpha-tubulin and beta-actin antibody (Cell Signaling
Technology, Danvers, MA), and anti-MANF antibody
(Abnova, Taipei City, Taiwan) at 1:1000 dilution. The
secondary antibodies conjugated to horseradish peroxidase
were obtained from Cell Signaling Technology. The
detection was performed by enhanced chemiluminescenceselect (GE Healthcare Bio-Sciences, Pittsburgh, PA). Fiji/
ImageJ was used for the quantiﬁcation of immunoblot.
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Quantitative PCR
Total RNA was extracted from INS-1 832/13 cells using the
RNeasy Mini Kit (Qiagen, Germantown, MD) and reverse
transcribed using High-Capacity cDNA Reverse Transcription Kits (Thermo Fisher Scientiﬁc). The expression of
Manf and ER stress-related genes including Binding
immunoglobulin protein (Bip), CCAAT/enhancer-binding
protein-homologous protein (Chop), spliced X-box binding
protein (Xbp1) (sXbp1), and Tribbles Pseudokinase 3
(Trb3) were detected by quantitative PCR (qPCR) using
SYBR green reagents (Bio-Rad Laboratories). The qPCR
was performed in triplicate for each sample. The primers
sequences were: rat Manf, 5′-TGAGGTATCGAAGC
CTCTGG-3′ and 5′-CTCGCAGATCTGGCTGTCTT-3′;
rat actin, 5′-GCAAATGCTTCTAGGCGGAC-3′ and 5′AAGAAAGGGTGTAAAACGCAGC-3′; rat Bip, 5′-TGG
GTACATTTGATCTGACTGGA-3′ and 5′-CTCAAAGGT
GACTTCAATCTGGG-3′; rat Chop, 5′-AGAGTGGTC
AGTGCGCAGC-3′ and 5′-CTCATTCTCCTGCTCCTTC
TCC-3′; rat sXbp1, 5′-CTGAGTCCGAATCAGGTGC
AG-3′ and 5′-ATCCATGGGAAGATGTTCTGG-3′; rat
Trb3 5′-ACCATGCGAGCCACATCTCTG-3′ and 5′-CT
AGCCATACAGCCCCACCTC-3′.

Primary islet culture
Mouse primary islets were taken from βWfs1(−/−) mice. The
mice were anesthetized, and pancreata were infused with 5 ml
of 0.45 mg/ml collagenase type V (MilliporeSigma) in Hank’s
balanced salt solution without Ca2+ (Thermo Fisher Scientiﬁc). After surgical removal, pancreata were incubated for
12 min at 37 °C, and then hand-shaken for 2 min. Undigested
acinar tissue was removed by using a 70-μm cell strainer and
recovered tissues were washed twice with ice-cold Hanks’
balanced salt solution followed by centrifugation at 1100 rpm
for 1 min. Islets were handpicked and preincubated in RPMI
1640 medium containing 10% FBS and antibiotics before
experimentation. Islets of equal size were handpicked to
generate 3–5 technical replicates for all experiments. Very
large and very small islets were excluded. The results were
obtained from at least three independent experiments.

Human islet culture
Human islets were purchased from Prodo Laboratories (Aliso
Viejo, CA), and cultured in CMRL-1066 medium (Corning
Incorporated, Corning, NY) containing 5 mM glucose, 100
units/ml penicillin, 100 µg/ml streptomycin, 2 mM GlutaMAX (Thermo Fisher Scientiﬁc), 250 µg/ml gentamycin
(Thermo Fisher Scientiﬁc), 10 mM HEPES (pH 7.4) (Thermo
Fisher Scientiﬁc), and 10% FBS. Human islets (30 islets/
well) were handpicked under a dissecting microscope.

A soluble endoplasmic reticulum factor as regenerative therapy for Wolfram syndrome

Insulin secretion assay
Primary mouse islets or INS-1 832/13 were cultured for 24 h
and batches of ten islets were handpicked on the day of the

1199

experiment. Mouse islets or INS-1 832/13 were starved for
1 h in Krebs-Ringer bicarbonate-HEPES buffer (129 mM
NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4,
1.2 mM MgSO4, 10 mM HEPES, and 1 mM CaCl2 at
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Fig. 1 MANF expression and secretion are induced by ER calcium
depletion leading to suppression of ER stress-mediated cell death.
a qPCR analysis monitoring Manf mRNA expression levels in INS-1
832/13 cells treated with thapsigargin (TG) 10 nM for 24 h, 0.1 µM or
0.5 µM for 6 h. UT untreated (n = 3, ***P = 0.0001, ****P < 0.0001).
b Western blot analysis monitoring extracellular and intracellular
MANF levels. INS-1 832/13 cells were treated with 0.5 µM of TG for
indicated times. c Left panel: western blot for evaluating the expression level of MANF protein in wild type (WT) and Manf knockout
(Manf-KO) INS-1 832/13 cells. Right panel: caspase-3/7 activity
normalized to cell viability in INS-1 832/13 cells treated with or
without TG (0.1 µM for 4 h) (n = 8, ****P < 0.0001). d Western blot
of cleaved caspase-3 in INS-1 832/13 cells pretreated with or without
recombinant MANF peptide (5 µg/ml) for 24 h, and then challenged
with TG (0.5 µM) for 6 h. Quantiﬁcation of immunoblot analysis is
shown in the right panel (n = 4, ****P < 0.0001). e The caspase-3/7
activity assay in INS-1 832/13 cells pretreated with recombinant
MANF peptide (5 µg/ml) for 24 h, and then challenged with TG
0.5 µM for 6 h. f Left panel: western blot for evaluating the expression
level of MANF protein in control (Ctrl) and MANF overexpressed
INS-1 832/13 (MANF-OE) whole cell lysate and supernatant. Right
panel: qPCR analysis monitoring the expression levels of Chop,
sXbp1, Trb3, and Bip mRNA in Ctrl and MANF-OE INS-1 832/13
cells challenged with TG 0.5 µM for 6 h (n = 3, *P < 0.05, **P < 0.01,
****P < 0.0001).

pH 7.4) containing 0.1% bovine serum albumin (KRBH/
BSA). KRBH/BSA was supplemented with 2.8 mM glucose
and then stimulated for 1 h at 37 °C in KRBH/BSA containing basal 5.5 mM or stimulatory 16.7 mM glucose. At
the end of each incubation, supernatants were collected to
measure insulin release, and cellular insulin contents were
determined by acid–ethanol extraction followed by ELISA
Rat/Mouse Insulin kit (MilliporeSigma).

Cell proliferation
The islets isolated from humans donor or βWfs1(−/−) mice
were dissociated by incubation with 0.25% trypsin-EDTA
(Thermo Fisher Scientiﬁc) at 37 °C for 5 min and treated
with MANF peptide (R&D Systems, Minneapolis, MN) 5
µg/ml for 5 days. Two-thirds of the medium were changed
daily to fresh medium with MANF peptide. To monitor the
cell proliferation rate, the BrdU cell proliferation assay kit
(Cell Signaling Technology) was used following the manufacturer’s instruction.

Caspase-3/7 activity in INS-1 832/13 cells
INS-1 832/13 cells were cultured in RPMI medium in a 96well plate. Cells were treated with MANF peptide (5 µg/ml)
for 24 h, and then exposed to thapsigargin (MilliporeSigma). Caspase-3 activity and cell viability were
assessed using the Caspase-Glo® 3/7 assay kit and the
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CellTiter-Fluor™ cell viability Assay kit (Promega Corp.,
Madison, WI).

Immunostaining
Pancreatic tissue sections were ﬁxed, rehydrated and permeabilized with 0.1% Triton X-100 for 2 min. The sections
were washed with 0.1% Tween-20 PBS (PBS-T) containing
Image-It FX signal enhancer (Thermo Fisher Scientiﬁc) for
1 h and incubated with primary antibodies overnight at 4 °C
[guinea pig anti-insulin antibody (1:100, Thermo Fisher
Scientiﬁc), MANF (1:100, Abnova), and Ki67 (1:100, Cell
Signaling Technology)]. The tissue sections were washed
three times in PBS-T and incubated with secondary antibodies for 1 h at room temperature. Images were obtained
with a Zeiss LSM 5 PASCAL confocal microscope with
LSM Image software.

Measurement of β-cell mass
For measurement of β-cell mass, every 40th pancreatic
section was immunostained with guinea pig anti-insulin
antibody (1:100, Thermo Fisher Scientiﬁc) and counterstained with hematoxylin. The β-cell mass for each mouse
was quantiﬁed using Image Pro Plus software (Media
Cybernetics, Rockville, MD) by obtaining the fraction of
the cross-sectional area of pancreatic tissue (exocrine and
endocrine) positive for insulin staining, and then multiplying this by the pancreatic weight.

Measurement of apoptosis through TUNEL assay
Apoptotic cells were detected using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
method as per the manufacturer’s protocol (MilliporeSigma). For the determination of apoptosis, all β-cells
per pancreatic sections (ﬁve sections per animal) were
analyzed to count the total number of TUNEL-positive βcells. An average of 150 islets was counted per animal and
the percentage of TUNEL-positive cells was quantitated.

In vivo administration of AAV vectors
The methods for AAV production are described in Supplemental Information. AAV was produced in collaboration with the Hope Center Viral Vectors Core at
Washington University. Male (n = 3, 2–3 months of age)
and female (n = 4, 3–4 months of age) βWfs1(−/−) mice
received intraperitoneal injections of AAV9-CBA-IRESGFP or AAV9-CBA-MANF-IRES-GFP at a ﬁnal dose of
1 × 1013 viral genome particles diluted in saline per
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Fig. 2 Effect of MANF on glucose-stimulated insulin secretion. a
Doxycycline-inducible shRNA directed against Wfs1 (INS-1 DOXshWfs1) cells were treated with or without MANF peptide (5 µg/ml) for
24 h, and then treated with doxycycline (DOX). Insulin release was
measured at basal (5.5 mM) glucose and stimulatory (16.7 mM) glucose
conditions (n = 3, not signiﬁcant). b Cellular insulin contents were
measured after the 24 h pretreatment with MANF peptide (5 µg/ml)

followed by DOX treatment (n = 3, not signiﬁcant). c Glucose-stimulated
insulin secretion on control (Ctrl) and MANF overexpressed INS-1 832/
13 cells (MANF-OE). Insulin release was measured at 5.5 and 16.7 mM
glucose conditions (n = 3, not signiﬁcant). d Primary islets isolated from
wild type (WT) and β cell-speciﬁc Wfs1 knockout mice (βWfs1(−/−)) were
pretreated with MANF peptide (5 µg/ml) for 24 h. Insulin release was
measured at 5.5 mM and 16.7 mM glucose (n = 3, not signiﬁcant).

mouse. After 4 weeks of AAV administration, the pancreata were harvested. Dissected pancreas pieces were
ﬁxed in 4% formalin. Formalin-ﬁxed parafﬁn-embedded
sections were deparafﬁnized and rehydrated. To estimate
the β-cell replication rate, pancreatic sections were
immunostained with anti-insulin and anti-Ki-67 antibody,
a marker for cellular proliferation. Overall, 1500–3000 β
cells were counted in each animal.

Results

Data analysis
The values are expressed as mean ± SEM. All the statistical
analysis was carried out with Prism 8 (ver 8.0.2). Comparisons among the group were done by Student’s t test. Multiple
comparisons were performed by ANOVA followed by
Tukey’s test. P < 0.05 was considered statistically signiﬁcant.

MANF confers protection against cell death induced
by ER calcium depletion
We have recently shown that various β cell perturbants,
including the loss of function of Wolfram syndrome 1
(WFS1) gene, induce ER calcium depletion and ER stress,
leading to β cell death [10, 22]. It has been recently reported
that loss of MANF in vivo leads to β cell death with ER
stress elevation [20]. These considerations prompted us to
monitor MANF expression levels in β cells under stressed
conditions. Although Manf mRNA expression was not
changed by Wfs1 deﬁciency (Fig. S1), thapsigargin, which
is a well-established ER calcium depletion inducer,
increased Manf mRNA expression and MANF protein

1202

secretion in INS-1 832/13 cells (Fig. 1a, b). A smaller band
of extracellular MANF corresponds to an isoform lacking
RTDL domain which is prone to be secreted, and a larger
band corresponds to an isoform containing RTDL domain
which is glycosylated [15] (https://www.ncbi.nlm.nih.gov/
protein/NP_001101653.1,XP_006243837.1). Intracellular
fraction only contains an isoform with the C-terminal RTDL
domain [23]. While Manf knockout INS-1 832/13 cells
were more sensitive to ER stress-induced cell death
(Fig. 1c), recombinant MANF peptide pretreatment reduced
cell death in INS-1 832/13 cells treated with thapsigargin
(Fig. 1d, e). Furthermore, mRNA expression level of tribbles pseudokinase 3 (Trb3), which is an ER stress-inducible
gene, was signiﬁcantly suppressed in INS-1 832/13 cells
stably overexpressing MANF (MANF-OE) (Fig. 1f). Trb3
is a proapoptotic component of ER stress signaling [24–26],
suggesting that MANF might suppress the proapoptotic arm
of ER stress signaling in those models.

Effect of MANF on insulin secretion
Since the loss of MANF in vivo can lead to β cell dysfunction, we studied the relationship between MANF and
insulin secretion. We created INS-1 832/13 cells in which
Wfs1 expression can be suppressed by doxycyclineinducible shRNA directed against Wfs1 (INS-1 DOXshWfs1) [9]. Glucose-stimulated insulin secretion (GSIS)
assays were performed in INS-1 DOX-shWfs1 cells,
MANF-OE INS-1 832/13, and primary mouse islets isolated
from β cell-speciﬁc Wfs1 knockout (βWfs1(−/−)) mice treated with recombinant MANF peptide. As a consequence,
MANF treatment or overexpression did not affect GSIS in
those models (Fig. 2a–d).

MANF activates proliferation of human primary
islets
The fact that the suppression of ER stress can lead to β cell
proliferation raised the possibility that MANF treatment
might activate β cell proliferation [22, 23]. To test this idea,
human primary islets were treated with recombinant MANF
peptide and then their proliferation rates were assessed by
the BrdU assay. Consequently, MANF treatment signiﬁcantly induced the proliferation of human primary islets
derived from two out of six donors (Fig. 3 and Supplementary Table).

MANF-based treatment for Wolfram syndrome
We have previously shown that ER calcium depletion,
followed by ER stress-mediated cell death, plays a role in
the pathogenesis of Wolfram syndrome [10, 22, 27], which
prompted us to consider the possibility that MANF-based
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Fig. 3 MANF activates proliferation of β cells. The BrdU assay
monitoring the proliferation of human primary islets treated with or
without MANF peptide (5 µg/ml) for 5 days (n = 4, *P < 0.05).

treatment could prevent β cell death and activate β cell
proliferation in Wolfram syndrome. Cell death induced by
Wfs1 knockdown in INS-1 DOX-shWfs1 cells was prevented by recombinant MANF peptide treatment shown as
cleaved caspase-3 protein and caspase-3/7 activity reduction
(Fig. 4a, b). The proliferation of primary islets from
βWfs1(−/−) mice, which is a mouse model of Wolfram
syndrome [21], was also enhanced by MANF treatment
(Fig. 4c). Moreover, MANF treatment suppressed the
expression of proapoptotic ER stress markers (Chop and
Trb3) in INS-1 DOX-shWfs1 cells (Fig. 4d) and MANF
overexpression improved the viability of Wfs1 knockout
INS-1 832/13 cells (Fig. S2).
Next, we analyzed the effect of MANF on β cell proliferation in βWfs1(−/−) mice. Adeno-associated virus 9
expressing MANF (AAV9-MANF) was injected intraperitoneally into βWfs1(−/−) mice. We then monitored β cell
proliferation for 5 weeks after the injections. Pancreas
sections from those mice showed robust expression of
MANF in islet β cells, as well as in exocrine pancreatic cells
(Fig. 5a). We found that β cell proliferation rates in endocrine cells were higher in βWfs1(−/−) mice injected with
AAV9-MANF than in those injected with control AAV9
(Fig. 5b). β cell mass was not increased in both groups
(Fig. 5c). TUNEL-positive cells were rarely detectable in
both groups (βWfs1(−/−) mice injected with AAV9-control,
0.09 ± 0.02%; βWfs1(−/−) mice injected with AAV9-MANF,
0.08 ± 0.02%) (Fig. 5a). Although MANF was also overexpressed in exocrine pancreatic cells, proliferation rates of
these cells were comparable with control cells, suggesting
that the proliferative effect of MANF might be speciﬁc for
pancreatic β cells (Fig. S3). Collectively, these results
indicate that MANF enhances β cell survival and proliferation in cell and mouse models of Wolfram syndrome.
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Fig. 4 MANF attenuates cell death and activates cell proliferation
in β cell models of Wolfram syndrome. a Immunoblot analysis of
cleaved caspase-3 and actin in doxycycline-inducible shRNA directed
against Wfs1 (INS-1 DOX-shWfs1) cells. INS-1 DOX-shWfs1 cells
were untreated or pretreated with MANF peptide (5 μg/ml) for 24 h,
and then treated with doxycycline (DOX) for Wfs1 suppression. The
quantiﬁed ratio of cleaved caspase-3 is shown in the right panel (n = 3,
*P < 0.05). b Caspase-3/7 activity assay in INS-1 DOX-shWfs1 cells.
INS-1 DOX-shWfs1 cells were untreated or pretreated with MANF
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peptide (5 μg/ml) for 24 h, and then treated with or without DOX for
another 48 h (n = 3, **P < 0.01). c BrdU assay of β cell-speciﬁc Wfs1
knockout mice (βWfs1(−/−)) primary islets. The isolated islets were
treated with or without MANF peptide (5 µg/ml) for 5 days (n = 4,
*P < 0.05). d qPCR analysis monitoring the expression levels of Chop,
sXbp1, Trb3, and Bip mRNA in INS-1 DOX-shWfs1 cells. The cells
were treated with or without MANF peptide (5 μg/ml) for 24 h, and
then treated with DOX (n = 3, *P < 0.05).
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Fig. 5 Overexpression of MANF by AAV9 enhances β cell proliferation in a mouse model of Wolfram syndrome. a Top panels:
double immunoﬂuorescence staining of insulin (green ﬂuorescence)
and MANF (red ﬂuorescence) on pancreatic tissue sections from β
cell-speciﬁc Wfs1 knockout mice (βWfs1(−/−)) taken 5 weeks after
intraperitoneal injection of AAV-control (AAV9-CBA-IRES-GFP) or
AAV9-MANF (AAV9-CBA-MANF-IRES-GFP) vector (n = 6 each
group). Middle panels: double immunoﬂuorescence staining of insulin
(green ﬂuorescence) and Ki67 (red ﬂuorescence) of pancreatic sections
from βWfs1(−/−) mice taken 5 weeks after intraperitoneal injection of
AAV-control or AAV9-MANF vector (n = 6 in each group). Bottom
panels: double immunoﬂuorescence staining of insulin (green ﬂuorescence) and TUNEL staining (red ﬂuorescence) of pancreatic sections
from βWfs1(−/−) mice taken 5 weeks after intraperitoneal injection of
AAV-control or AAV9-MANF vector (n = 6 each group). The magniﬁcation is ×10 for each image, and ×40 for the right upper images.
b Quantiﬁcation of Ki67-positive β cells in AAV-control or AAV9MANF injected βWfs1(−/−) mice (AAV-control, n = 5; AAV9-MANF,
n = 6; *P < 0.05). c Quantiﬁcation of β cell mass in AAV-control or
AAV9-MANF injected βWfs1(−/−) mice (n = 6 in each group, not
signiﬁcant).

Discussion
Wolfram syndrome is characterized by juvenile-onset diabetes, optic nerve atrophy and, neurodegeneration due to
ER stress-mediated cell death [6, 28], and has been established as a prototype of ER stress disease [8, 9, 11–14,
21, 29]. Since there is no treatment that can stop or even
slow the progression of this syndrome currently, developing
the novel treatment has been an urgent task.
Increasing evidence indicates that MANF possesses
regenerative and cytoprotective effects. In the mouse pancreas, MANF overexpression was found to induce the
proliferation of pancreatic β cells [20]. Systematic MANF
overexpression or recombinant MANF peptide delivery
protects the liver of old mice from inﬂammation and
hepatocyte apoptosis [30]. Notably, recombinant human
MANF peptide protects human β cells from cytokineinduced ER stress and cell death, and induces β cells proliferation [31]. In this study, we show that MANF treatment
activates the proliferation of β cells in human islets and
prevents ER stress-mediated β cell death and enhances β
cell proliferation in cell and mouse models of Wolfram
syndrome. These results broaden the possibility of developing the new treatments for Wolfram syndrome using
adeno-associated virus expressing MANF or recombinant
MANF peptide. To elucidate the efﬁcacy of MANF treatment, further experiments using the other Wolfram syndrome model mice, or β cells which are differentiated from
Wolfram syndrome patient-derived iPSCs would be
required [12]. On the other hand, MANF treatment did not
change insulin secretion and insulin content in INS-1 832/
13 cells. These results are in line with the previous report
using EndoC-βH1 cells [31]. Moreover, even though
MANF overexpression activated the βWfs1(−/−) mice β cell
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proliferation, the β cell mass of these mice was not changed.
A longer overexpression might be needed to study the effect
of MANF on the β cell mass.
MANF was originally isolated from astrocytes as a novel
neurotrophic factor [15]. It has been reported that MANF
regulates the NF-kB signaling pathway, which is considered
to be activated through their receptors [31, 32]. However,
receptors for MANF have not been identiﬁed. Further studies are required to identify these receptors and their signaling pathway in order to develop treatments based on
small molecules that act as MANF receptor agonists.
Our results are also relevant to other diseases related to
ER stress. Genetic, clinical, and experimental evidence
indicates that ER stress-mediated cell death is an important
pathogenic component in human chronic disorders,
including type 1 and type 2 diabetes, retinal degeneration,
Parkinson’s disease, amyotrophic lateral sclerosis, inﬂammatory bowel disease, and multiple sclerosis [3, 33–39]. It
has been reported that plasma MANF protein levels decline
with age in ﬂies, mice, and human [30]. In contrast, circulating MANF levels are known to increase in children with
type 1 diabetes as compared with control subjects [40]. ER
stress in β cells has been linked to autoimmunity and
cytokine-mediated β cell death during the onset and progression of type 1 diabetes [41–47]. Thus, increased MANF
levels in patients with type 1 diabetes may be an adaptive
response to ER stress in β cells. MANF mutations have
been reported in a patient with type 2 diabetes [48]. In such
disorders, MANF-based therapy may suppress ER stressmediated cell death and delay the progression of the disease.
Collectively, our results provide a rationale for identifying signaling molecules regulated by MANF, including its
receptor, so that we may develop novel regenerative therapy
for ER stress-related disorders, including diabetes, retinal
degeneration, and Wolfram syndrome.
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